Journal
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 128, Issue 2, Pages 328-U339Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2011.02.042
Keywords
Investigative bronchoscopy; safety; severe asthma; exacerbation
Categories
Funding
- NHLBI
- National Institutes of Health (NIH)/NHLBI
- NIH-NIAID
- Novartis
- AstraZeneca
- GlaxoSmithKline
- MedImmune
- Ception
- Asthmatx
- Amgen
- Genentech
- Merck
- NIH
- Elsevier
- state of Ohio
- Aerovance
- Ception Therapeutics
- Icagen
- [HL69116]
- [HL69130]
- [HL69155]
- [HL69167]
- [HL69170]
- [HL69174]
- [HL69349]
- [HL091762]
- [M01 RR03186]
- [M01 RR007122-14]
- [1UL1RR024992]
- [1UL1RR024989]
- [1UL1RR025011]
- Medical Research Council [G1000758, G1000758B] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish
Ask authors/readers for more resources
Background: Investigative bronchoscopy was performed in a subset of participants in the Severe Asthma Research Program to gain insights into the pathobiology of severe disease. We evaluated the safety aspects of this procedure in this cohort with specific focus on patients with severe asthma. Objective: To evaluate prospectively changes in lung function and the frequency of adverse events related to investigative bronchoscopy. Methods: Bronchoscopy was performed by using a common manual of procedures. A subset of very severe asthma was defined by severe airflow obstruction, chronic oral corticosteroid use, and recent asthma exacerbations. Subjects were monitored for changes in lung function and contacted by telephone for 3 days after the procedure. Results: A total of 436 subjects underwent bronchoscopy (97 normal, 196 not severe, 102 severe, and 41 very severe asthma). Nine subjects were evaluated in hospital settings after bronchoscopy; 7 of these were respiratory-related events. Recent emergency department visits, chronic oral corticosteroid use, and a history of pneumonia were more frequent in subjects who had asthma exacerbations after bronchoscopy. The fall in FEV1 after bronchoscopy was similar in the severe and milder asthma groups. Prebronchodilator FEV1 was the strongest predictor of change in FEV1 after bronchoscopy with larger decreases observed in subjects with better lung function. Conclusion: Bronchoscopy in subjects with severe asthma was well tolerated. Asthma exacerbations were rare, and reduction in pulmonary function after the procedure was similar to that in subjects with less severe asthma. With proper precautions, investigative bronchoscopy can be performed safely in severe asthma. (J Allergy Clin Immunol 2011;128:328-36.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available